We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.185 | 0.17 | 0.20 | 368,320 | 08:00:04 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -859k | -0.0012 | -1.50 | 1.34M |
From May 2019 to May 2024
TIDMNFX
RNS Number : 9532X
Nuformix PLC
16 August 2018
16 August 2018
Nuformix Plc
("Nuformix" or the "Company")
2018 Annual Financial Report and Notice of Annual General Meeting
The Company announces that the following documents were posted to its shareholders:
-- Annual Financial Report 2018 -- 2018 Notice of Annual General Meeting and Proxy Form
A full pdf version of the Annual Financial Report 2018 together with the Notice of Annual General Meeting and sample Proxy Form are available for download from the Document Center section on the Company's website www.nuformix.com.
Copies of the Annual Financial Report 2018 and the Notice of 2018 Annual General Meeting and Proxy Form have been submitted to the National Storage Mechanism and will be available for inspection in due course at http://www.morningstar.co.uk/uk/NSM. The Nuformix Annual Financial Report will be filed with the Registrar of Companies in due course and copies can be obtained from the Company Secretary, SGH Company Secretaries Limited, 60 Gracechurch Street, London, EC3V 0HR.
The Annual General Meeting will be held on Wednesday 19 September 2018 at 1.00 pm at the offices of Shakespeare Martineau, 6(th) floor, 60 Gracechurch Street, London, EC3V 0HR.
For further information please contact:
Nuformix plc
Dan Gooding, Chief Executive Officer
+44 (0)1223 423 667
SGH Company Secretaries Ltd
Ben Harber
+44 (0)207 264 4366
Gable Communications Ltd
John Bick or Justine James
+44 (0)20 7193 7463
About Nuformix plc: www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NOASFMEFIFASESA
(END) Dow Jones Newswires
August 16, 2018 02:01 ET (06:01 GMT)
1 Year Nuformix Chart |
1 Month Nuformix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
